{"id":379,"date":"2023-07-05T19:06:04","date_gmt":"2023-07-05T23:06:04","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=379"},"modified":"2023-07-05T19:06:04","modified_gmt":"2023-07-05T23:06:04","slug":"beauty-and-personal-care-products-post-mocra-regulatory-compliance-checklist","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2023\/07\/05\/beauty-and-personal-care-products-post-mocra-regulatory-compliance-checklist\/","title":{"rendered":"Beauty and Personal Care Products Post-MoCRA Regulatory Compliance Checklist"},"content":{"rendered":"<p>MoCRA, Pub. L. No. 117-328, represents the first major statutory change to the authority of the Food and Drug Administration (FDA) to regulate cosmetics since the Food, Drug, and Cosmetics Act (FDCA), 21 U.S.C. \u00a7 361 et seq.,<br \/>\nin 1938 and the Fair Packaging and Labeling Act (FPLA), 21 C.F.R. \u00a7 701.3, in 1966.<\/p>\n<p>This checklist outlines key regulatory compliance considerations that are specific to personal care products marketed in the United States following the enactment of the federal Modernization of Cosmetics Regulation Act (MoCRA) on December 23, 2022.<\/p>\n<p>To read the full text of this <em>Lexis Nexis Practical Guidance Checklist<\/em> by Duane Morris attorneys <a href=\"https:\/\/www.duanemorris.com\/attorneys\/driscollrugarte.html\" target=\"_blank\" rel=\"noopener\">Driscoll Ugarte<\/a>, <a href=\"https:\/\/www.duanemorris.com\/attorneys\/frederickrball.html\" target=\"_blank\" rel=\"noopener\">Rick Ball<\/a>, <a href=\"https:\/\/www.duanemorris.com\/attorneys\/alysonbwalker.html\" target=\"_blank\" rel=\"noopener\">Alyson Lotman<\/a>, <a href=\"https:\/\/www.duanemorris.com\/attorneys\/kellyabonner.html\" target=\"_blank\" rel=\"noopener\">Kelly Bonner<\/a> and <a href=\"https:\/\/www.duanemorris.com\/attorneys\/coleenwhill.html\" target=\"_blank\" rel=\"noopener\">Coleen Hill<\/a>, please <a href=\"https:\/\/www.duanemorris.com\/articles\/static\/beauty_personal_care_post_mocra_checklist_0723.pdf\" target=\"_blank\" rel=\"noopener\">visit the firm website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MoCRA, Pub. L. No. 117-328, represents the first major statutory change to the authority of the Food and Drug Administration (FDA) to regulate cosmetics since the Food, Drug, and Cosmetics Act (FDCA), 21 U.S.C. \u00a7 361 et seq., in 1938 and the Fair Packaging and Labeling Act (FPLA), 21 C.F.R. \u00a7 701.3, in 1966. This &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2023\/07\/05\/beauty-and-personal-care-products-post-mocra-regulatory-compliance-checklist\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Beauty and Personal Care Products Post-MoCRA Regulatory Compliance Checklist&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[640,605,628,658,29,639,641,657,119],"ppma_author":[521],"class_list":["post-379","post","type-post","status-publish","format-standard","hentry","category-general","tag-alyson-walker-lotman","tag-coleen-hill","tag-cosmetics","tag-driscoll-ugarte","tag-fda","tag-kelly-bonner","tag-mocra","tag-regulations","tag-rick-ball"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=379"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/379\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=379"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}